[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545157":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":107,"collaborators":22,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":22,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":22,"studyType":122,"phases":123,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"RemeGen Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Disitamab Vedotin Intravesical instiliations :Dose escalation cohort","EXPERIMENTAL","Participants will receive Disitamab Vedotin for injection Intravesical instiliations into the bladder for 1 hour, D1, once a week.",[13],"Drug: Disitamab Vedotin for injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Disitamab Vedotin for injection","Intravesical instiliations into the bladder",[9],[21],"RC48",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Hong Luo","CONTACT","+8610-58075763","hong.luo@remegen.com",[30,46,59,71,83,95],{"facility":31,"status":32,"city":33,"state":34,"zip":22,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Sun Yat-sen Memorial Hospital,SunYat-sen University","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":38,"coordinates":39},"Point",[40,41],113.25,23.11667,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":22,"phoneExt":22,"email":22},"Tianxin Lin, Ph.D",{"facility":47,"status":48,"city":49,"state":50,"zip":22,"country":35,"countryCode":36,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Tongji Hospital","NOT_YET_RECRUITING","Wuhan","Hubei",{"type":38,"coordinates":52},[53,54],114.26667,30.58333,{"lat":54,"lon":53},[57],{"name":58,"role":26,"phone":22,"phoneExt":22,"email":22},"Shaogang Wang, M.D",{"facility":60,"status":32,"city":61,"state":62,"zip":22,"country":35,"countryCode":36,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Hunan Cancer hospital","Changsha","Hunan",{"type":38,"coordinates":64},[65,66],112.97087,28.19874,{"lat":66,"lon":65},[69],{"name":70,"role":26,"phone":22,"phoneExt":22,"email":22},"Shusuan Jiang, M.D",{"facility":72,"status":48,"city":73,"state":74,"zip":22,"country":35,"countryCode":36,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The first affiliated hospital with nanjing medical universtity","Nanjing","Jiangsu",{"type":38,"coordinates":76},[77,78],118.77778,32.06167,{"lat":78,"lon":77},[81],{"name":82,"role":26,"phone":22,"phoneExt":22,"email":22},"qiang Lv, M.D",{"facility":84,"status":48,"city":85,"state":86,"zip":22,"country":35,"countryCode":36,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"West China Hospital","Chengdu","Sichuan",{"type":38,"coordinates":88},[89,90],104.06667,30.66667,{"lat":90,"lon":89},[93],{"name":94,"role":26,"phone":22,"phoneExt":22,"email":22},"Peng Zhang, M.D",{"facility":96,"status":48,"city":97,"state":98,"zip":22,"country":35,"countryCode":36,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Tianjin Medical University Second Hospital","Tianjin","Tianjin Municipality",{"type":38,"coordinates":100},[101,102],117.17667,39.14222,{"lat":102,"lon":101},[105],{"name":106,"role":26,"phone":22,"phoneExt":22,"email":22},"Hailong Hu, M.D",{"type":108,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100545157","phase-1-to-evaluate-the-safety-efficacy-and-pharmacokinetics-of-intravesical-instiliations-of-disitamab-vedotin-in-patients-with-high-risk-non-muscular-invasive-bladder-cancer-nmibc-that-express-her2-100545157",false,"NCT06378242","To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","An Single-arm, Multicenter Phase I\u002FII Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","Inclusion Criteria:\n\n1. Voluntary consent to participate in the study and signed the informed consent form.\n2. Male or female, age 18-75 years (including both).\n3. Histologic confirmed non-muscle invasive bladder urothelial carcinoma (NMIBC), and the risk group met the high-risk (including very high-risk) group.\n\n   Note: High-risk NMIBC is a high-grade \u002F G3 tumor meeting any of the following:\n\n   a.Carcinoma in situ (CIS) b. T1 stage c. diameter\\>3cm d.Multiple tumors, or recurrent tumors.\n4. Absence of resectable disease（Ta and\u002For T1 disease） after transurethral resection (TURBT) procedures (residual CIS acceptable;\n5. The urologist assessed that radical surgery for bladder cancer was not suitable or the subject refused radical surgery for bladder cancer.\n6. Tumor tissue samples were detected by immunohistochemistry (IHC) to satisfy HER2 expression of 1+, 2+ or 3+.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n8. Adequate heart, bone marrow, liver, kidney and coagulation function\n\nExclusion Criteria:\n\n* 1\\. Invasive bladder cancer (T2 and above) and \u002F or with regional lymph node and distant metastasis.\n\n  2\\. Combined urothelial carcinoma outside the bladder (i. e., urethra, ureter or renal pelvis).\n\n  3\\. Any other antitumor therapy received within 4 weeks before study administration, .\n\n  4 Subjects plan to undergo major surgery during the study or within 4 weeks before the first dose.\n\n  5, Known allergic to DV and its components or to any excipients.","ALL","18 Years","75 Years",{"count":120,"type":121},24,"ESTIMATED","INTERVENTIONAL",[124,125],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2",[128],"High-risk Non-muscle Invasive Bladder Cancer",[130,131,132],"HER2-expression","High-risk non-muscle invasive bladder cancer","intravesical instiliations","2024-07-09",{"date":135,"type":136},"2024-07-11","ACTUAL",{"date":138,"type":136},"2024-06-14",{"date":140,"type":121},"2029-12-31",{"name":5,"class":6},6]